
Research and Publications
Featured Publications
[White paper] Don't Forget to Look Both Ways: Driving Diversity and Inclusion in Clinical Research
Lowering the barriers to high-quality researchers is core to the mission behind Smart Omix. In the spirit of our launch, our team explores the technological, economic and cultural barriers to entering the field, and how these barriers impacting the diversity of the ecosystem overall.
Download the white paper.
A decentralized, prospective observational study to collect real-world data from patients with myasthenia gravis using smartphones
UCB and Sharecare report results from a 3-month prospective observational study in adults with myasthenia gravis (MG) using fully decentralized methods, to assess the feasibility of real-world data collection from smartphones for patients with this rare disease at MGFA 2022.
Predicting Environmental Allergies from Real-World Data
Using Smart Omix, a proprietary digital clinical research platform powering mobile research studies, the Sharecare team developed and trained a machine-learning algorithm to predict the emergence and severity of symptoms related to allergic rhinitis.
Empowering Clinical Research in a Decentralized World
Our paper in Nature Digital Medicine highlights the implications of new technologies, including edge computing, zero-trust environments, and federating computing in DCTs enabled by digital health technologies can offer improvements in real-time data acquisition remotely while maintaining privacy and security.
Watch the movie, not the trailer
Download our white paper on how pharmaceutical companies can use Smart Omix to easily collect real-world data at scale, streamline processes and gain a richer, more comprehensive picture of an individual's health.
In the News
Findings from a real-world smartphone data collection study reaffirm UCB’s commitment to delivering pioneering, tailored care solutions for individuals living with gMG
Learn more about our work with UCB. Beyond demonstrating that decentralized, smartphone-based methods to collect real-world data from gMG patients are feasible and may provide enhanced visibility into the burden of the disease, the study also identified unique clusters of exacerbation subtypes with specific symptom representation.
Developing objective symptom measures with UCB Biopharma
doc.ai, now, a Sharecare company, an enterprise AI platform accelerating digital transformation in healthcare, and UCB, a multinational biopharma company headquartered in Brussels, Belgium, today announced a new collaboration in AI medical research with the launch of a digital health trial for myasthenia gravis, a neuromuscular disease that can lead to impaired speech, blurred vision, difficulty swallowing, and other symptoms.
The right tech can add real-world context to clinical trials.
SVP of Clinical Product and Innovation, Dr. Francesca Rinaldo, speaks to Outsourcing Pharma about how Smart Omix can provide researchers with the tools to unlock the potential of decentralized real-world clinical research. Conducting trials in a decentralized manner will no longer be a "nice to have" but a "need to have."